Johnson & Johnson (JNJ)

Healthcare · Pharmaceuticals · Price $265.77
Updated: Aug 28, 2026
Excellent Capital Efficiency — Healthcare
ROIC of 18.19% is above the 18% threshold Zyberno applies to Healthcare businesses — a level typically associated with durable competitive advantages.
ROIC
18.19%
Return on Invested Capital
ROE
25.74%
Return on Equity
ROA
10.60%
Return on Assets
Invested Capital
$134.0B
Debt + Equity
Operating Income
$25.2B
EBIT (TTM)

🧮 JNJ ROIC Calculation

ROIC = NOPAT / Invested Capital
Operating Income (EBIT) $25.2B
NOPAT (After-Tax Operating Profit) $25.1B
Total Debt $49.0B
Shareholders' Equity $85.0B
Invested Capital (Debt + Equity) $134.0B
ROIC (Return on Invested Capital) 18.19%

Understanding ROIC

Return on Invested Capital (ROIC) measures how efficiently a company uses its capital (both debt and equity) to generate profits. For JNJ, the current ROIC is 18.19%.

Why ROIC is the Best Quality Metric

Charlie Munger famously said: "Over the long term, it's hard for a stock to earn a much better return than the business which underlies it earns." ROIC is superior to other return metrics because it measures returns on ALL capital employed — both debt and equity. Companies with consistently high ROIC often have durable competitive advantages (moats).

This is not just investing folklore. In Zyberno's survivorship-free audit of 16 fundamental metrics on the complete S&P 500 (2010–2024), ROIC was the single most predictive screen of them all — the widest return spread of any metric tested, stable across both halves of the period — and it out-predicted ROE, the most popular quality metric, roughly seventeen-to-one on identical firms.

ROIC Benchmarks

Excellent: >20%

Indicates a potential economic moat. The company generates exceptional returns on capital, suggesting strong competitive advantages.

Good: 12-20%

Above-average capital efficiency. The company creates value for shareholders by earning returns well above its cost of capital.

Average: 8-12%

Typical for most companies. Returns roughly match the weighted average cost of capital (WACC) for many businesses.

Poor: <8%

Below cost of capital for many companies. May indicate the company is destroying value through poor capital allocation.

ROIC vs ROE vs ROA

ROE: 25.74% →

Return on Equity only measures returns on shareholder equity. Can be inflated by high leverage. In Zyberno's 16-screen audit, ROIC out-predicted ROE roughly seventeen-to-one on identical firms.

ROA: 10.60%

Return on Assets measures returns on total assets. Useful but doesn't distinguish between debt and equity financing.

Owner Earnings: $17.8B →

Buffett's preferred earnings metric. ROIC tells you how efficiently capital is used; Owner Earnings shows the actual cash generated.

Free Cash Flow: $17.8B →

Actual cash after capex. High ROIC companies typically generate strong free cash flow relative to their invested capital.

What to Look For

📊 Full JNJ Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

📈 JNJ ROE

Compare ROIC to Return on Equity and understand the impact of leverage on returns.

💹 JNJ P/E Ratio

Analyze valuation relative to earnings — how the market prices JNJ's profitability.

👤 JNJ Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💵 JNJ Free Cash Flow

See actual cash generation after capital expenditures.

💰 JNJ Net Income

See the bottom-line profit that drives ROE calculations.

View Full JNJ Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
$73.65
🛡️
Margin of Safety
Valuation Gap
-100.0%
🎯
Expected Return
Projected Annual
-25.7%
Click any metric for full methodology and detailed analysis

Summary: JNJ Capital Efficiency

Johnson & Johnson (JNJ) has a ROIC of 18.19%, which Zyberno classifies as excellent for a Healthcare company — above the 18% threshold Zyberno applies to healthcare businesses where R&D investment and regulatory barriers shape capital returns. Combined with an ROE of 25.74% and ROA of 10.60%, Zyberno uses ROIC as its primary measure of capital quality because it accounts for both debt and equity and is harder to inflate with leverage. For complete financial analysis, view the full JNJ stock report on Zyberno.

Frequently Asked Questions

What is JNJ's current ROIC?

Johnson & Johnson's Return on Invested Capital (ROIC) is 18.19%, measured against the 18% excellent threshold Zyberno applies to Healthcare businesses. ROIC measures how efficiently the company generates returns on both debt and equity capital.

Is JNJ's ROIC good?

Johnson & Johnson (JNJ) has a ROIC of 18.19%, which Zyberno classifies as excellent for a Healthcare company — above the 18% threshold Zyberno applies to healthcare businesses where R&D investment and regulatory barriers shape capital returns.

What is the difference between ROIC and ROE?

ROIC measures returns on ALL capital (debt + equity), while ROE only measures returns on shareholder equity. JNJ's ROIC is 18.19% vs ROE of 25.74%. ROE can be artificially inflated by high debt levels, making ROIC a more reliable quality metric.

Why do Buffett and Munger focus on ROIC?

Warren Buffett and Charlie Munger focus on ROIC because it measures the true efficiency of capital allocation. High ROIC companies can reinvest profits at attractive rates, creating compounding wealth over time.

📊 Full JNJ Stock Report

See JNJ's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

📈 JNJ ROE

Compare to Return on Equity and understand the impact of leverage on returns.

💹 JNJ P/E Ratio

Analyze the price-to-earnings ratio and earnings yield as a valuation metric.

🎯 JNJ Earnings Surprise (SUE)

See whether JNJ is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 JNJ Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 JNJ Net Income

See the bottom-line profit that drives return calculations.

📊 JNJ EPS

Earnings per share — net income on a per-share basis.

View Full JNJ Report Find More Quality Stocks
Scroll to Top